Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.

Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies. Oncologist. 2021 06; 26(6):476-482.

View in: PubMed

subject areas

Carcinoma, Renal Cell
Everolimus
Humans
Kidney Neoplasms
Phenylurea Compounds
Protein Kinase Inhibitors
Quinolines
Receptors, Vascular Endothelial Growth Factor
Retrospective Studies
Vascular Endothelial Growth Factor A

authors with profiles

NIZAR M TANNIR
ERIC JONASCH
THARAKESWARA K BATHALA
AMISHI YOGESH SHAH